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Asthma is a complex and heterogeneous respiratory disorder characterized by chronic 
airway inflammation. It has generally been associated with allergic mechanisms related 
to type 2 airway inflammation. Nevertheless, between 10 and 33% of asthmatic 
individuals have nonallergic asthma (NA). Several targeted treatments are in clinical 
development for patients with Th2 immune response, but few biomarkers are been 
defined for low or non-Th2-mediated inflammation asthma. We have recently defined 
by gene expression a set of genes as potential biomarkers of NA, mainly associated 
with disease severity: IL10, MSR1, PHLDA1, SERPINB2, CHI3L1, IL8, and PI3. Here, 
we analyzed their protein expression and specificity using sera and isolated peripheral 
blood mononuclear cells (PBMCs). First, protein quantification was carried out using 
ELISA (in sera) or Western blot (proteins extracted from PBMCs by Trizol procedure), 
depending on the biomarker in 30 healthy controls (C) subjects and 30 NA patients. 
A receiver operating characteristic curve analysis was performed by using the R pro-
gram to study the specificity and sensitivity of the candidate biomarkers at a gene- and 
protein expression level. Four kinds of comparisons were performed: total NA group 
vs C group, severe NA patients vs C, moderate–mild NA patients vs C, and severe NA 
patients vs moderate–mild NA patients. We found that all the single genes showed 
good sensitivity vs specificity for some phenotypic discrimination, with CHI3L1 and 
PI3 exhibiting the best results for C vs NA: CHI3L1 area under the curve (AUC) (CI 
95%): 0.95 (0.84–1.00) and PI3 AUC: 0.99 (0.98–1.00); C vs severe NA: PI3 AUC: 1 
(0.99–1.00); and C vs moderate–mild NA: CHI3L1 AUC: 1 (0.99–1.00) and PI3 AUC: 
0.99 (0.96–1.00). However, the results for discriminating asthma disease and severity 
with protein expression were better when two or three biomarkers were combined. 
In conclusion, individual genes and combinations of proteins have been evaluated as 
reliable biomarkers for classifying NA subjects and their severity. These new panels 
could be good diagnostic tests.
Keywords: biomarkers, gene expression, nonallergic asthma, protein expression, severity, receiver operating 
characteristic
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inTrODUcTiOn
Asthma is a complex respiratory disorder defined in the most 
recent Global Initiative for Asthma (1) as “a heterogeneous disease, 
usually characterized by chronic airway inflammation.” Asthma 
diagnosis is based on a history of respiratory symptoms, such as 
wheezing, shortness of breath, chest tightness, and cough, which 
varies over time and fluctuates in intensity. The World Health 
Organisation defines asthma as the most common chronic disease 
in children and estimates that more than 300 million people are 
affected (2). However, one of the major problems in defining this 
pathology is its wide clinical spectrum. It is generally accepted 
that clinical differences in treatment response and disease course 
are related to multiple underlying variations in genetic, pharma-
cologic, physiologic, biologic, and/or immunologic mechanisms 
that produce subclasses of phenotypes termed endotypes (3).
Despite this clinical heterogeneity, allergic mechanisms have 
been implicated in 50–80% of asthmatic patients and in approxi-
mately 50% of severe asthma (4, 5). Thus, asthma has generally 
been associated with type 2 airway inflammation characterized 
by elevated levels of immunoglobulin E, eosinophils, and several 
interleukins (IL), such as IL-4, IL-5, IL-13, and IL-9. Nevertheless, 
10–33% of asthmatic individuals have nonallergic asthma (NA), 
or allergic sensitization that cannot be demonstrated (6). The 
generally accepted definition of NA includes negative skin prick 
or in vitro-specific IgE tests to a panel of local allergens, and at a 
minimum, a panel of perennial allergens; total serum IgE levels 
are typically normal or low (<150 IU/ml) (7). The mechanisms 
contributing to the non-type 2 immune response in asthmatic 
patients are less clear. Two major mechanisms leading to neu-
trophilic inflammation are postulated: dysregulated neutrophil-
mediated immune responses due to respiratory infections (8) or 
defects in resolution of inflammation (9), and the activation of the 
IL-17-dependent pathway (10–14).
New strategies for the discovery and validation of biomarkers 
such as omics have been used to reveal the mechanisms respon-
sible for asthma endotypes in different tissues. A biomarker is an 
objective, quantifiable biological parameter which serves as an 
index for health and physiological assessment. It could be the sign 
of a complex underlying via or an essential molecule associated 
directly with a main role in one endotype of a disease. Along 
these lines, many biomarkers targeted treatments are in clinical 
development for patients with Th2 immune response: anti-IL-4/
IL-13, anti-IL-4, anti-IL-5, anti-IgE antibodies, and CRTh2 
(chemoattractant receptor-homologous molecule expressed on 
Th2 cell antagonists) (15–17), although in the latter case, two 
recently conducted large Phase 2 studies with CRTh2 antagonists 
have either failed to demonstrate significant efficacy in clinical 
endpoints compared to placebo (18) or showed a similar degree of 
improvement with the active control (19) in patients with atopic/
allergic asthma.
Besides, to date, no endotype-driven interventions have been 
proven effective for non-type 2 immune response asthma (20). In 
summary, more information is needed to optimize the patient’s 
therapeutic responses while avoiding adverse effects (20).
Against this backdrop, our research team has recently defined 
a group of genes that was differentially expressed in peripheral 
samples from nonallergic asthmatic patients (low or non-Th2 
inflammation) and mainly associated with disease severity (21, 22). 
The current study assessing gene and protein biomarkers is a 
follow up of our previous study (21, 22). Here, we explore the 
relevance of the gene and protein expression of these potential 
biomarkers according to sensitivity and specificity analysis 
[receiver operating characteristic (ROC) curves]. The ultimate 
aim is to provide useful new biomarkers for the NA disease.
MaTerials anD MeThODs
subjects
The study population comprised 60 unrelated subjects: 30 healthy 
control subjects (C) and 30 patients with NA. The samples of the 
asthma group came from the asthma biobank of the CIBERES 
located at the IIS-Fundación Jiménez Díaz-UAM in Madrid (IIS-
FJD-UAM) (21, 22). These patients were diagnosed with severe, 
moderate, or mild asthma according to the Spanish Guidelines 
for the Management of Asthma, or GEMA (23). The daily mean 
of inhaled corticosteroids during the last 6  months, previous 
the diagnosis, and while taking the sample was: 1,488 ± 541 µg 
in severe asthma, 1,100 ±  977.75  µg in moderate asthma, and 
450 ± 463.68 µg in mild asthma. On the day of extraction of the 
sample, the subjects did not take any medication.
Pulmonary function tests were carried out by determining 
the predicted percentage of forced vital capacity (% FVC), forced 
expiratory volume in 1 s (% FEV1), and the post bronchodilator 
test (% PBD) or reversibility test.
The control subjects were healthy, with no history of respiratory 
diseases. They were diagnosed at the Allergy Service of two hos-
pitals in Andalusia (Spain), Vírgen del Rocío University Hospital 
in Seville and San Cecilio University Hospital in Granada, and the 
samples were sent to the IIS-FJD-UAM to be processed.
All the subjects, controls, and NA patients, were tested by skin 
prick test against a panel of common allergens, including mites 
(Dermatophagoides pteronyssinus, Dermatophagoides farinae, and 
Lepidoglyphus destructor), epithelia (cat and dog), cockroaches 
(Blatella orientalis and Blatella germanica), pollens (Cypress, 
banana shadow, olive, mixture of grasses, Artemisia, Parietaria, 
and Salsola), and fungi (Alternaria, Cladosporium, Aspergillus, 
and Penicillium).
Informed consent in accordance with the Declaration of 
Helsinki was obtained from each subject. Ethical approval for the 
study was obtained from the ethical and research committees of 
the participating hospitals.
Peripheral Blood Mononuclear cells 
(PBMc) isolation and Protein extraction
Peripheral blood mononuclear cells were isolated from heparin-
containing peripheral blood samples by gradient centrifugation 
using Lymphoprep (Comercial Rafer, Zaragoza, Spain) following 
the manufacturer’s instructions. PBMCs were isolated in steril 
conditions using endotoxin-free reagents. Total proteins were iso-
lated from PBMCs (106 cells) using the Trizol method (Invitrogen, 
Carlsbad, CA, USA). Protein levels were quantified by the BCA 
method (Thermo Fisher Scientific, Rockford, IL, USA).
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gene selection
CD86, IL10, MSR1, PHLDA1, SERPINB2, CHI3L1, CPA3, IL8, 
and PI3 were selected as candidate biomarkers of the NA group 
(significance established at a relative gene quantification higher 
than 4 or lower than 0.25 comparing the C group) (21).
CD86 and CPA3 did not meet the strict criteria (RQ>4 or 
<0.25) in all of the comparisons (21), so we did not examine their 
expression at the protein level.
soluble Protein level analysis of il-10, 
chi3l1, il-8, Pi3, and POsTn
Soluble biomarkers with an ELISA commercial available were 
quantified through this technique.
Levels of IL-10, CHI3L1, IL-8, PI3, and POSTN were measured 
in the subjects’ serum using the human ELISA kits manufactured 
by ImmunoTools (Friesoythe, Germany) for IL-10; by R&D 
Systems (Minneapolis, MN, USA) for CHI3L1, PI3, and POSTN; 
and by Diaclone (Besancon Cedex, France) for IL-8. The pro-
cedure was carried out in accordance with each manufacturer’s 
protocol.
POSTN or periostin was analyzed at protein level given its 
relevance in the literature as a protein associated with asthma 
(24, 25).
Protein analysis of Msr1, PhlDa1,  
and serPinB2
Protein determination of MSR1, PHLDA1, and SERPINB2 was 
performed by Western blot because they were not soluble proteins 
or no ELISA commercial kit was available for their study. MSR1 
was analyzed in 9 C and 18 NA patients (8 severe NA patients 
and 10 with moderate–mild diagnosis), PHLDA1 was studied 
in 8 C and 5 NA (3 severe and 2 moderate–mild patients), and 
we studied SERPINB2 in 6 C and 11 NA subjects (6 with severe 
asthma and 5 with moderate–mild diagnosis). The Western 
blot procedure used was that of the Invitrogen Western Breeze® 
Chemiluminescent Western Blot Immunodetection Kit (Life 
Technologies, Carlsbad, CA, USA) previously described (21). The 
primary antibody used to detect MSR1 was the rabbit anti-human 
polyclonal CD204/macrophage scavenger receptor I antibody 
(dilution 1:2,500) by ThermoFisher Scientific. PHLDA1 was 
detected with a rabbit anti-human polyclonal PHLDA1 antibody 
(Thermo Fisher Scientific) at a 1:500 dilution and SERPINB2 with 
the rabbit anti-human polyclonal SERPINB2 antibody by R&D 
Systems at a dilution of 1:250. Data of specific protein results were 
relative to β-Actin (dilution 1:1,000; Cell Signaling Techonology, 
Danvers, MA, USA) expression using the ImageQuant LAS 4000 
(GE Healthcare Life Science).
rOc curve analysis at the gene  
and Protein level
The ROC curve plots sensitivity vs specificity and the area under 
the curve (AUC) is an effective measure of accuracy for evaluating 
the diagnostic ability of tests to discriminate the true state of sub-
jects, finding optimal cutoff values. A ROC curve was performed 
for the candidate biomarkers of the NA group, examining severity 
and expression at the genetic and protein level. Four kinds of 
comparisons were performed: total NA group vs C group, severe 
NA patients vs C group, moderate–mild NA patients vs C group, 
and severe NA patients vs moderate–mild NA patients. As a 
guide for interpreting the ROC curves, the following intervals 
have been established for AUC values: 0.50–0.60, poor test; 
0.61–0.75, regular test; 0.76–0.90, good test; 0.91–0.97, very good 
test; 0.98–1, excellent test. Besides, only the results with a CI 95% 
between 0.70 and 1 were considered statistically relevant.
statistical analysis
The levels and relative expression of the proteins studied were 
compared among groups by unpaired t-test, using the Graph-Pad 
InStat 3 program. Statistical significance was established in two-
tailed P value <0.05. The ROC curve analyses were performed by 
using the R program.
resUlTs
subjects
The demographic and clinical parameters of the population 
studied are summarized in Table 1. The NA patients were sig-
nificantly older than the C subjects. The mean levels of total IgE 
were similar between the two groups, 75.02 ± 128.21 IU/ml in 
healthy control subjects vs 82.04 ± 80.63 IU/ml in NA patients 
(p>0.05). However, % FEV1 and % FVC showed statistically 
significant differences between severe NA vs moderate–mild NA 
patients (66.33 ± 16.62 vs 85.38 ± 21.03, P = 0.0127 in % FEV1; 
69.93 ±  19.94 vs 94 ±  19.52, P =  0.0031 in % FVC) (data not 
shown). Percentage and number of eosinophils in the NA group 
were normal (3.83 ± 2.24 vs 273.86 ± 137.13 cells/μl) (cutoff: 1–4% 
and 50–450 cells/μl). No significant differences were found in the 
presence of eosinophils between severe and moderate–mild NA 
subjects (percentage: 3.73 ± 2.48 vs 4.22 ± 1.25%, respectively; 
number: 264 ± 152.96 vs 310 ± 52.57 cells/μl, respectively) (data 
not shown). Skin prick test against a panel of common allergens 
was negative in all the participants in this study. Concomitant 
diseases in the NA group were: nonatopic rhinitis (80%), sinusitis 
(56%), polyposis (33.3%), and esophageal reflux (20%).
rOc curve analysis at the genetic level
The genes studied were grouped into five categories based on the 
ROC curve analysis results (Table 2) (see Material and Methods).
Comparing the total subjects of the C and NA groups, we 
found that all genes fell into the “good” test category, except 
CHI3L1 and PI3 which obtained very good and excellent rat-
ings, respectively. The results according to the severity of the NA 
group varied. When comparing C to moderate/mild NA subjects, 
MSR1, IL10, CPA3, PHLDA1, and SERPINB2 maintained their 
“good” status, while IL8 moved to a better ranking (very good), 
and CD86 lowered to “regular.” PI3 also maintained its excellent 
test position, joined by CHI3L1. The comparisons between C and 
severe NA patients differed from the overall analysis in some of 
the genes studied. While IL8, CPA3, PHLDA1, and SERPINB2 
stayed in the good test category and PI3 continued to be excellent, 
MSR1, IL10, and CD86 moved up to the “very good” test position, 
and CHI3L1 was lowered to “good.”
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CD86 was the only good biomarker for asthma-severity dis-
crimination. The rest of the genes were found to be “regular” or 
“poor” for discriminating moderate–mild NA from severe NA 
patients.
Protein expression
SERPINB2 and PHLDA1 were quantified in the total protein 
extracted from PBMCs. Levels of IL-10, CHI3L1, PI3, and 
POSTN proteins were measured in the sera of the study popula-
tion. Relative quantification and mean sera levels (expressed as 
pg/ml) are summarized in Figure 1. Only SERPINB2 and POSTN 
showed statistically significant differences. For SERPINB2, the 
control group (0.66 ± 0.31) had a higher expression than the total 
NA patients (0.11 ±  0.05, P <  0.0001). These differences were 
also shown when the C group was compared with the severe NA 
(0.13 ± 0.07, P = 0.0019) and moderate–mild NA (0.09 ± 0.03, 
P = 0.0029) groups. In contrast, the protein levels of POSTN were 
higher in the total NA group (18,679.59 ± 8,086.07 pg/ml), as well 
as in the severe (20,198.91 ± 7,859.24 pg/ml) and, in the moder-
ate–mild NA patients (17,160.28 ± 7,930.59 pg/ml) compared to 
the C group (15,487.71 ± 6,532.85 pg/ml), but only in the severe 
asthma patients were the differences statistically significant.
Though there were no statistically significant differences in 
the other proteins studied, a tendency was observed when the 
NA patients were analyzed according to severity. The IL-10 levels 
were higher in severe (200.60 ± 219.85 pg/ml) diagnosed subjects 
compared to C subjects (123.38 ± 120.61 pg/ml) and to moder-
ate–mild NA patients (105.27 ± 79.62 pg/ml). This same tendency 
was observed in PI3: severe NA group: 6,225.03 ± 1,999.11 pg/
ml, moderate–mild NA group: 5,824.14 ± 2,624.29 pg/ml, and 
C subjects: 6,056.30 ±  2,535.83  pg/ml. In contrast, PHLDA1 
and CHI3L1 showed the highest levels in moderate–mild 
NA patients (moderate–mild NA: 0.08  ±  0.10; severe NA: 
0.05 ± 0.07; C: 0.04 ± 0.05 for PHLDA1; and moderate–mild NA: 
21,702.56 ± 11,589.97 pg/ml; severe NA: 17,026.99 ± 4,845.20 
pg/ml; C: 15,729.18  ±  8,576.85  pg/ml for CHI3L1). Protein 
expression of MSR1 and IL-8 were previously discussed (22). 
Briefly, IL-8 protein expression showed slight but non-significant 
differences between severe (505.49 ± 387.8 pg/ml) and moder-
ate–mild (377.7 ±  338.27  pg/ml) NA patients; and for MSR1 
two proteic bands were found by Western blot, with distinct 
behaviors. The lower molecular weight band showed statistical 
differences between C subjects and NA subjects.
rOc curve analysis at the Protein level
The MSR1’s lower band and SERPINB2 were the best individual 
biomarkers at the protein level according to the ROC curve 
results (Table 2). These two biomarkers were classified as “very 
good” for comparing the whole group of NA and severe patients 
vs the control group. For discriminating the moderate–mild 
patients from controls, the MSR1’s lower band was “excellent” 
and SERPINB2 was “good.”
Overall, all other biomarkers fell into the “poor” or “regular” 
test category (Table  2). PI3, IL-10, and MSR1’s upper band 
would be considered poor biomarkers. The same was the case for 
CHI3L1 and IL-8, except when classifying severe NA patients and 
when discriminating moderate–mild from severe patients in the 
TaBle 2 | Classification of biomarkers by the receiver operating characteristic (ROC) curves analysis.
comparison/aUc (ci 95%) excellent test (0.98–1) Very good (0.91–0.97) good (0.76–0.90) regular (0.61–0.75) Poor (0.5–0.60)
(a) gene expression level
C vs NA PI3, 0.99 CHI3L1, 0.95 IL8, 0.90
MSR1, 0.89
CPA3, 0.88
IL10, 0.87
SERPINB2, 0.84
PHDLA1, 0.83
CD86, 0.81
C vs MM CHI3L1, 1
PI3, 0.99
IL8, 0.91 CPA3, 0.88
SERPINB2, 0.86
MSR1, 0.82
IL10, 0.79
PHDLA1, 0.77
CD86, 0.71
C vs S PI3, 1 MSR1, 0.94
IL10, 0.94
CD86, 0.91
CHI3L1, 0.89
IL8, 0.89
PHLDA1, 0.89
CPA3, 0.88
SERPINB2, 0.82
MM vs S CD86, 0.78 MSR1, 0.66
CPA3, 0.65
PHDLA1, 0.62
PI3, 0.60
IL8, 0.53
IL 10, 0.51
SERPINB2, 0.51
(B) Protein expression level
C vs NA MSR1 low, 0.96
SERPINB2, 0.91
POSTN, 0.62 CHI3L1, 0.6
MSR1 up, 0.6
IL8, 0.5
PI3, 0.5
IL10, PHLDA1<0.5
C vs S MSR1 low, 0.93
SERPINB2, 0.93
CHI3L1, 0.63
IL8, 0.62
MSR1 up, 0.60
IL10, 0.56
POSTN, 0.55
PI3, 0.52
PHLDA1, ND
C vs MM MSR1 low, 1 SERPINB2, 0.89 POSTN, 0.69
IL8, 0.62
MSR1 up, 0.6
CHI3L1, 0.56
PI3, 0.51
IL10<0.5
PHLDA1, ND
MM vs S IL8, 0.76 SERPINB2, 0.7
POSTN, 0.65
CHI3L1, 0.62
PI3, 0.55
MSR1 low, 0.55
IL10, MSR1 up<0.5
PHLDA1, ND
Summary of the ROC curve analysis of the most important biomarkers by comparison. AUC: area under the curve. ND: non-determined because of lack of data. C: control 
group. NA: total nonallergic asthma group. MM: group of subjects with moderate–mild asthma. S: group of subjects with severe asthma. MSR1 low: MSR1’s lower band protein 
expression. MSR1 up: MSR1’s upper band protein expression.
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case of CHI3L1, and for IL-8 (when comparing moderate–mild 
and severe patients to healthy subjects), whose expression rose to 
“regular.” Additionally, IL-8 was able to discriminate moderate–
mild from severe patients with a good AUC value (0.76). POSTN 
was classified as “regular” when comparing the total and the 
moderate–mild NA subjects and “poor” for the severe patients.
Given the poor results obtained in the individual ROC curve 
study of several biomarkers, an analysis of the AUC values com-
bining two and three biomarkers was carried out.
The results of the analysis combining two proteins are 
summarized in Table 3. There was an improvement of the sen-
sitivity and the specificity or synergy when several biomarkers 
were combined in the discrimination of total NA vs C groups 
(Table 3A): this is the case for MSR1’s upper band + MSR1’s lower 
band, CHI3L1 + MSR1’s upper band and POSTN + PHLDA1.
When the analyses performed were comparing moder-
ate–mild NA subjects and the C group (Table  3B), the results 
showed strong synergies between CHI3L1  +  MSR1’s upper 
band, CHI3L1  +  SERPINB2, IL-8  +  PI3, IL-8  +  POSTN, 
POSTN +  MSR1’s upper band, and POSTN +  SERPINB2. In 
the comparison of severe NA subjects (Table 3C) with C group, 
the improvement of the AUC values was observed in the MSR1’s 
upper band + MSR1’s lower band, CHI3L1 + MSR1’s lower band, 
and in POSTN + SERPINB2.
FigUre 1 | Mean levels of the protein expression. (a) Mean levels of SERPINB2. (B) Mean levels of PHLDA1. (c) Mean levels of IL10. (D) Mean levels of CHI3L1. 
(e) Mean levels of PI3. (F) Mean levels of POSTN. *Statistically significant comparison (P < 0.0001) between the C and the group selected. #Statistically significant 
comparison (P < 0.05) between the C and the group selected. Protein levels of SERPINB2 and PHLDA1 were measured by Western Blot in 6 C and 11 NA subjects 
(6 with severe asthma and 5 with moderate–mild diagnosis) and 8 C and 5 NA (3 severe and 2 moderate–mild patients), respectively. Densitometric analysis was 
done in individual blots (by the ImageQuant LAS 4000 software, as it is explained in Section “Materials and Methods”) using β-actin protein for normalization. IL-10, 
CHI3L1, PI3, and POSTN were quantified by ELISA in all the patients of the study population. Abbreviations: C, control group; NA, total nonallergic asthma group; S 
NA, group of subjects with severe asthma; MM NA, group of subjects with moderate–mild asthma.
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The combination of three biomarkers (Table  4) gave very 
interesting combinations, with AUC values over 0.75, meaning 
that good, very good, or excellent test were found for discriminat-
ing asthma and its severity from the control population. In the 
case of the total NA group (Table 4A), the following synergies 
were of great sensitivity and specificity: CHI3L1 + PI3 + MSR1’s 
upper band, CHI3L1  +  POSTN  +  MSR1’s upper band, 
CHI3L1 + POSTN + PHLDA1, CHI3L1 + POSTN + SERPINB2, 
PI3 + POSTN + MSR1’s upper band, PI3 + POSTN + PHLDA1, 
and PI3 + POSTN + SERPINB2. The analysis of the moderate–
mild NA patients compared with the C group (Table 4A) shared 
several combinations of biomarkers with the total NA group: 
CHI3L1 + PI3 + MSR1’s upper band, PI3 + POSTN + MSR1’s 
upper band, and PI3 + POSTN + SERPINB2, but particular of this 
comparison were CHI3L1 + IL-8 + PI3, CHI3L1 + IL-8 + POSTN, 
and IL-8 + PI3 + POSTN. The discrimination of severe patients 
from control subjects shared combinations of biomarkers with the 
other two comparisons. Important synergies were observed with 
PI3 + POSTN + MSR1’s upper band and PI3 + POSTN + MSR1’s 
lower band. As well as in the moderate–mild patients, 
CHI3L1 +  IL-8 +  PI3 was an interesting combination for dis-
criminating severe subjects from C group.
The comparison between the moderate–mild NA and 
severe NA subjects was also performed (Table 2, Table 3D, and 
Table  4B). In the individual analysis, all the biomarkers were 
classified as “regular” or “poor,” except IL-8, whose AUC value 
was good. When two biomarkers were combined, the combina-
tions of CHI3L1 +  POSTN, IL10 +  POSTN, IL-8 +  PI3, and 
SERPINB2 +  POSTN were good to discriminate severe from 
moderate–mild asthma, and of smaller importance was the 
grouping of IL-8 + POSTN. In the three-biomarker analysis, the 
list of important synergies is longer (Table 4B).
There was an improvement of the sensitivity and the specificity 
or synergy when several biomarkers were combined, obtaining very 
interesting combinations, with AUC values over 0.75, meaning that 
good, very good, or excellent test were found for discriminating 
phenotypic conditions. Bringing together all the results, we estab-
lished a ranking of the best biomarkers or cluster of biomarkers able 
to discriminate each condition analyzed, with a predictive accuracy 
of at least very good (AUC > 0.75). These rankings are shown in 
Table 5. It is worth highlighting the permanent presence of POSTN 
in most of the combinations able to discriminate moderate–mild 
and severe NA patients, as well as the best combination for this 
discrimination, CHI3L1 + IL-8 + POSTN.
DiscUssiOn
There is a real need to improve the diagnosis and treatment of 
the asthmatic disease. Many efforts are being undertaken to define 
new biological therapies against specific targets that define asthma 
mediated by Th2 inflammation; however, a substantial number 
of asthmatic patients present low or non-Th2 inflammation. 
TaBle 3 | Receiver operating characteristic (ROC) curve analyses of the protein expression combining two biomarkers.
chi3l1 il-10 il-8 Pi3 POsTn Msr1 up Msr1 low PhlDa1 serPinB2
(a) Total nonallergic asthma (na) group compared with the control group
CHI3L1 0.60 0.48 0.67 0.59 0.63 0.78 0.97 0.70 0.92
IL-10 – 0.42 ND 0.59 0.47 ND ND ND ND
IL-8 – ND 0.50 0.61 0.74 ND ND ND ND
PI3 – – – 0.50 0.67 0.63 0.96 0.47 0.91
POSTN – – – – 0.62 0.73 0.96 0.82 0.95
MSR1 up – ND ND – – 0.60 1 ND ND
MSR1 low – ND ND – – – 0.96 ND ND
PHLDA1 – ND ND – – ND ND 0.42 ND
SERPINB2 – ND ND – – ND ND ND 0.91
(B) Moderate–mild na group compared with the control group
CHI3L1 0.56 0.41 0.63 0.56 0.70 0.83 ND ND 0.97
IL-10 – 0.41 ND 0.67 0.63 ND ND ND ND
IL-8 – ND 0.62 0.76 0.87 ND ND ND ND
PI3 – – – 0.51 0.69 0.61 ND ND 0.89
POSTN – – – – 0.69 0.81 ND ND 0.97
MSR1 up – ND ND – – 0.60 ND ND ND
MSR1 low ND ND ND ND ND ND 1 ND ND
PHLDA1 ND ND ND ND ND ND ND 0.48 ND
SERPINB2 – ND ND – – ND ND ND 0.89
(c) severe na group compared with the control group
CHI3L1 0.63 0.62 0.67 0.63 0.64 0.76 0.94 ND 0.93
IL-10 – 0.56 ND 0.51 0.60 ND ND ND ND
IL-8 – ND 0.62 0.46 0.57 ND ND ND ND
PI3 – – – 0.52 0.65 0.64 0.95 ND 0.93
POSTN – – – – 0.55 0.66 0.93 ND 0.97
MSR1 up – ND ND – – 0.60 1 ND ND
MSR1 low – ND ND – – – 0.93 ND ND
PHLDA1 ND ND ND ND ND ND ND 0.48 ND
SERPINB2 – ND ND – – ND ND ND 0.93
(D) Moderate–mild na group compared with the severe group
CHI3L1 0.62 0.43 0.76 0.56 0.77 0.68 0.65 ND 0.63
IL-10 – 0.47 ND 0.63 0.77 ND ND ND ND
IL-8 – ND 0.76 0.82 0.78 ND ND ND ND
PI3 – – – 0.55 0.57 0.60 0.60 ND 0.73
POSTN – – – – 0.65 0.64 0.62 ND 0.90
MSR1 up – ND ND – – 0.46 0.55 ND ND
MSR1 low – ND ND – – – 0.55 ND ND
PHLDA1 ND ND ND ND ND ND ND 0.48 ND
SERPINB2 – ND ND – – ND ND ND 0.70
In bold are the area under the curve values greater than 0.75, which are considered good, very good, or excellent tests. ND: non-determined because of lack of data. Cells with a 
dash refer to a comparison already shown in another cell of this table. MSR1 low: MSR1’s lower band protein expression. MSR1 up: MSR1’s upper band protein expression. In gray 
are indicated the individual ROC curve analysis of the protein expression of the nine biomarkers.
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We recently defined a group of genes differentially expressed in 
peripheral samples from nonallergic asthmatic patients (low or 
non-Th2 inflammation) and some of them, mainly associated with 
the severity of these diseases. In this report, we further explore the 
relevance of the gene and protein expression of these potential bio-
markers, through the analysis of their individual and/or combined 
TaBle 5 | Ranking of the best individual and combined proteic biomarkers for 
each discrimination.
area under the 
curve (aUc)  
(ic 95%) value
Threshold
(a) Biomarkers able to discriminate na patients from c group
MSR1 low
SERPINB2
0.96 (0.89–1.00)
0.91 (0.72–1.00)
0.148
0.404
MSR1 low + MSR1 up
CHI3L1 + MSR1 low
POSTN + SERPINB2
CHI3L1 + SERPINB2
POSTN + PHLDA1
CHI3L1 + MSR1 up
1
0.97 (0.91–1.00)
0.95 (0.85–1.00)
0.92 (0.77–1.00)
0.82 (0.59–1.00)
0.78 (0.60–0.95)
0.148, 0.208
13,064, 0.148
13,633, 0.404
13,064, 0.404
13,633, 0.011
13,064, 0.208
PI3 + POSTN + MSR1 low
CHI3L1 + POSTN + MSR1 up
PI3 + POSTN + MSR1 up
0.97 (0.90–1.00)
0.83 (0.67–0.98)
0.77 (0.58–0.96)
6,528, 13,633, 0.148
13,064, 13,633, 0.208
6,528, 13,633, 0.208
(B) Biomarkers able to discriminate the moderate/mild na patients 
from the c group
MSR1 low
SERPINB2
1
0.89 (0.66–1.00)
0.148
0.404
CHI3L1 + SERPINB2
POSTN + SERPINB2
IL-8 + POSTN
CHI3L1 + MSR1 up
POSTN + MSR1 up
IL-8 + PI3
0.97 (0.90–1.00)
0.97 (0.90–1.00)
0.87 (0.70–1.00)
0.83 (0.63–1.00)
0.81 (0.58–1.00)
0.76 (0.50–1.00)
13,064, 0.404
15,787, 0.404
677, 15,787
13,064, 0.208
15,787, 0.208
677, 3,074
CHI3L1 + IL-8 + POSTN
CHI3L1 + IL-8 + PI3
0.87 (0.70–1.00)
0.79 (0.55–1.00)
13,064, 677, 15,787
13,064, 677, 3,074
(c) Biomarkers able to discriminate the severe na patients from the 
c group
MSR1 low
SERPINB2
0.93 (0.80–1.00)
0.93 (0.78–1.00)
0.137
0.359
MSR1 low + MSR1 up
POSTN + SERPINB2
PI3 + MSR1 low
CHI3L1 + MSR1 low
CHI3L1 + MSR1 up
1
0.97 (0.87–1.00)
0.95 (0.85–1.00)
0.94 (0.83–1.00)
0.76 (0.50–1.00)
0.137, 0.254
13,633, 0.359
6,528, 0.137
14,367, 0.137
14,367, 0.254
PI3 + POSTN + MSR1 low
CHI3L1 + PI3 + MSR1 low
CHI3L1 + IL-8 + PI3
PI3 + POSTN + MSR1 up
0.96 (0.88–1.00)
0.95 (0.86–1.00)
0.79 (0.56–1.00)
0.77 (0.54–0.99)
6,528, 13,633, 0.137
14,367, 6,528, 0.137
14,367, 262, 6,528
6,528, 13,633, 0.254
(D) Biomarkers able to discriminate the moderate/mild na patients 
from the severe na group
IL-8 0.76 (0.49–1.00) 841
POSTN + SERPINB2
IL-8 + PI3
IL-8 + POSTN
CHI3L1 + POSTN
IL-10 + POSTN
0.90 (0.71–1.00)
0.82 (0.58–1.00)
0.78 (0.52–1.00)
0.77 (0.59–0.96)
0.77 (0.43–1.00)
17,419, 0.132
841, 4,845
841, 17,419
18,500, 17,419
105.2, 17,419
CHI3L1 + IL-8 + POSTN
PI3 + POSTN + SERPINB2
CHI3L1 + IL-8 + PI3
CHI3L1 + POSTN + MSR1 up
CHI3L1 + POSTN + MSR1 low
CHI3L1 + PI3 + MSR1 up
0.98 (0.92–1.00)
0.93 (0.78–1.00)
0.88 (0.69–1.00)
0.80 (0.57–1.00)
0.80 (0.57–1.00)
0.78 (0.53–1.00)
18,500, 841, 17,419
4,845, 17,419, 0.132
18,500, 841, 4,845
18,500, 17,419, 0.257
18,500, 17,419, 0.056
18,500, 4,845, 0.257
Summary of the best options for discriminating each condition, obtained from the 
ROC curve analysis of protein expression from each of the nine biomarkers, alone 
or in combination. C: control group. NA: nonallergic asthma group. MM: group of 
subjects with moderate–mild asthma. S: group of subjects with severe asthma. MSR1 
low: MSR1’s lower band protein expression. MSR1 up: MSR1’s upper band protein 
expression. Threshold means the proteic levels of each biomarker able to discriminate 
each condition, with the AUC indicated. In bold are marked the options with the best 
statistical power (CI 95% between 0.7 and 1).
TaBle 4 | Receiver operating characteristic (ROC) curve analysis of the protein 
expression combining three biomarkers.
(a) na compared with the c
combination of biomarkers na vs c area 
under the curve 
(aUc) value
MM vs c  
aUc value
s vs c  
aUc value
CHI3L1 + IL-10 + PI3 0.59 0.67 0.64
CHI3L1 + IL-10 + POSTN 0.53 0.63 0.64
CHI3L1 + IL-8 + PI3 0.67 0.79 0.79
CHI3L1 + IL-8 + POSTN 0.72 0.87 0.67
CHI3L1 + PI3 + POSTN 0.66 0.68 0.62
CHI3L1 + PI3 + MSR1 up 0.77 0.83 0.64
CHI3L1 + PI3 + MSR1 low 0.97 ND 0.95
CHI3L1 + PI3 + PHLDA1 0.70 ND ND
CHI3L1 + PI3 + SERPINB2 0.92 ND 0.93
CHI3L1 + POSTN + MSR1 up 0.83 0.88 0.76
CHI3L1 + POSTN + MSR1 low 0.97 ND 0.94
CHI3L1 + POSTN + PHLDA1 0.78 ND ND
CHI3L1 + POSTN + SERPINB2 0.94 ND ND
IL-10 + PI3 + POSTN 0.57 0.61 0.60
IL-8 + PI3 + POSTN 0.75 0.84 0.62
PI3 + POSTN + MSR1 up 0.77 0.81 0.77
PI3 + POSTN + MSR1 low 0.97 ND 0.96
PI3 + POSTN + PHLDA1 0.78 ND ND
PI3 + POSTN + SERPINB2 0.94 0.97 ND
(B) Moderate–mild na compared with the severe group
combination of biomarkers aUc value
CHI3L1 + IL-10 + PI3 0.63
CHI3L1 + IL-10 + POSTN 0.77
CHI3L1 + IL-8 + PI3 0.88
CHI3L1 + IL-8 + POSTN 0.98
CHI3L1 + PI3 + POSTN 0.76
CHI3L1 + PI3 + MSR1 up 0.78
CHI3L1 + PI3 + MSR1 low 0.68
CHI3L1 + PI3 + SERPINB2 0.73
CHI3L1 + POSTN + MSR1 up 0.80
CHI3L1 + POSTN + MSR1 low 0.80
CHI3L1 + MSR1 up + MSR1 low 0.68
IL-10 + PI3 + POSTN 0.77
IL-8 + PI3 + POSTN 0.82
PI3 + POSTN + MSR1 up 0.60
PI3 + POSTN + MSR1 low 0.60
PI3 + POSTN + SERPINB2 0.93
PI3 + MSR1 up + MSR1 low 0.60
POSTN + MSR1 up + MSR1 low 0.62
In bold are the AUC values greater than 0.75, which are considered good, very good, 
or excellent tests. C: control group. NA: total nonallergic asthma group. MM: group of 
subjects with moderate–mild asthma. S: group of subjects with severe asthma. MSR1 
low: MSR1’s lower band protein expression. MSR1 up: MSR1’s upper band protein 
expression.
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expression, in order to demonstrate their ability to discriminate 
asthma disease and severity. This study seeks to provide different 
panels of biomarkers associated with NA disease that could be use-
ful for the diagnosis and/or therapy of this phenotype of asthma.
The ideal biomarker should be sensitive, specific, simple to 
perform, non-invasive, and inexpensive if possible (26). In the 
present report, we have evaluated the potential of nine genes and 
proteins to serve as biomarkers using peripheral blood samples 
from healthy controls and nonallergic asthmatic patients. We 
first analyzed their ability to discriminate asthmatic patients 
from healthy controls; second, we examined their potential as 
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biomarkers of the degree of severity, comparing severe and/or 
moderate–mild patients with healthy control subjects; and last, 
we studied their potential to discriminate severity from moder-
ate–mild in nonallergic asthmatic disease. As summarized in 
Table 2, all the genes were able to discriminate any of the phe-
notypical condition (NA, severe NA, or mild/moderate NA) with 
AUC values from excellent to good (ranging from 1 to 0.77), with 
the only exception of CD86, which was the poor biomarker for 
discriminating moderate/mild NA patients from controls (AUC: 
0.71). According to these data, PI3, CHI3L1, and IL8 are the best 
gene biomarkers (excellent or very good AUC) for discriminating 
NA from healthy control subjects, as well as for discriminating 
NA moderate/mild patients from control subjects. These results 
are in concordance with the recent description of the protective 
effect of PI3 against adult asthma (27). PI3 or Elafin, is a potent 
inhibitor of serine proteases, which plays a central role in control-
ling excessive activity of neutrophil elastase. It is a modulator of 
many parameters that are critical for inflammation, although it 
has pleiotropic effects (28). CHI3L1 or YKL-40 is thought to play 
a role in tissue inflammation and remodeling (29), and its role 
as a possible biomarker has been reviewed in YKL-40 regulated 
signaling mechanisms (30). Also, correlations between YKL-40 
levels and neutrophilic inflammation have been described (31). 
Finally, IL8 (a member of the CXC chemokines) is considered to 
be one of the main mediators of the inflammatory response and 
very important for the survival and chemotaxis of neutrophils. 
It is secreted by several cell types and has been associated with 
several respiratory disorders (32).
These three biomarkers (PI3, CHI3L1, and IL8) are closely 
related to neutrophils, suggesting the relevance of this kind of 
cells in noneosinophilic nonallergic asthmatic disease and sever-
ity (data here cannot be demonstrated because neutrophils were 
not determined).
PI3, IL10, MSR1, and CD86 were the gene biomarkers that 
best discriminated controls from NA patients with severe clinical 
features. IL10 has pleiotropic effects in immunoregulation and 
inflammation (33). It has been extensively related with asthma 
and allergy diseases (34).
MSR1 or macrophage scavenger receptor type I, or CD204 
has been described in many cell locations (usually in tissues), 
such as vascular smooth muscle cells, endothelial cells, human 
lung epithelial cells, etc. (35). This fact increases its pathophysi-
ological potential, and has been described as a central pivot of 
health and disease (36). MSR1 was associated with asthma and 
was postulated by our group as a very good biomarker candidate 
for severity in several respiratory diseases (21).
CD86 or B7.2, encodes a type I membrane protein expressed 
on antigen-presenting cells (APCs) and which provides costimu-
latory signals necessary for the initiation, modulation, and regu-
lation of an effective T cell response. Most APCs constitutively 
express low levels of CD86, but following activation they are 
rapidly upregulated (37). Interestingly, in this study, CD86 was 
the only gene biomarker capable of discriminating severe NA 
from moderate–mild NA patients, featuring a good AUC value 
(0.76). CD86 was followed by MSR1 (AUC: 0.66), CPA3 (0.65), 
and PHLDA1 (0.62), which were classified as regular biomark-
ers for this discrimination. CPA3 or carboxypeptidase A3, is a 
metalloexopeptidase specifically expressed by mast cells (38). 
CPA3 was described as the best individual discriminator for 
eosinophilic asthma in a study of six gene biomarkers in sputum 
(39). PHLDA1 is a nuclear protein that has been postulated as 
a biomarker in the early detection and/or therapy of gastric 
cancer (40), but never before has been associated with asthma 
disease. Overall, these gene analyses strengthen our previous 
results and evidence the potential of these nine gene biomark-
ers. For that, the next step was to determine the effectiveness 
of these biomarkers at the protein level using when it was 
available (IL-10, CHI3L1, IL-8, and PI3) the serum-ELISA as 
a quantitative assay that is commonly useful to analyze soluble 
biomarkers due to its sensitivity, specificity, and simplicity. On 
the other hand, although our gene expression results did not 
revealed POSTN as a differential gene, we decided to include 
the analysis of periostin levels in the serum, as it is one of the 
main biomarkers described as indicator of Th2-inflammation 
(41, 42) and the serum periostin levels have been related to the 
response to anti-IL-13 therapy in patients with moderate–mild 
asthma (43).
The individual protein biomarkers results are summarized 
in Table 2. MSR1’s lower band and SERPINB2 were the best 
individual biomarkers for discriminating the NA group and its 
severity from healthy control subjects. SERPINB2 is a member 
of the group of inhibitors of the serine protease family, enzymes 
that inhibit protease cathepsin G neutrophils and chymase of 
mast cells. SERPINB2 has been detected in different cell types, 
playing a role in inflammation and remodeling (44). It has 
been tentatively suggested that SERPINB2 represents a novel 
effector of the multiple airway remodeling actions provoked 
by IL-13 (45). It has been described, together with POSTN 
and chloride channel accessory 1, as a gene-signature for Th2 
asthma and mainly IL-13 asthma phenotype (41), but until 
our knowledge, SERPINB2 protein expression has only been 
studied in broncoalveolar lavage (BAL) and never before at a 
peripheral level.
IL-8 was the only individual protein biomarker with a good 
predictive accuracy for discriminating clinical severity between 
moderate–mild vs severe patients (AUC: 0.76), although with 
a moderate statistical power (CI 95%, 0.49–1). These results 
could highlight the relevance of IL-8 and indirectly confirm the 
recent publication in BAL, describing that neutrophils and IL-8 
are the only inflammatory components that distinguish con-
trolled from uncontrolled asthma (46), but should be confirmed 
in a larger population. In this regard, novel small molecules 
targeting neutrophilic inflammation, such as chemokine (CXC) 
receptor 2 (CXCR2) antagonists have been analyzed in the 
noneosinophilic asthma context, showing how these antago-
nists reduce neutrophils, but do not improve clinical outcomes 
in studies to date (47). Ligands for the CXCR2 receptor include 
the chemokines CXCL8 (IL-8). Recent studies indicate that 
while selective CXCR2 antagonists were found to significantly 
lower airway neutrophil counts in a mechanistic 1-month pilot 
study in more severe asthmatics (48), a lack of efficacy was 
observed in a larger 6-month clinical Ph2 trial [n = 640] spe-
cifically targeting CXCR2/IL-8 pathway in this defined asthma 
population (49).
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